Biotherapy for breast cancer refers to a broad class of treatments that use biological substances or harness the body’s own systems to fight tumor cells, and it has fundamentally changed how many breast cancers are treated. The category includes monoclonal antibodies, antibody-drug conjugates, immune checkpoint inhibitors, PARP inhibitors, CDK4/6 inhibitors, cancer vaccines, adoptive cell therapies, and oncolytic viruses. Some of these are well-established standard care, while others remain experimental. The specifics of which biotherapy applies depend heavily on the molecular subtype of the cancer, making breast cancer treatment more personalized than almost any other solid tumor.
What Counts as Biotherapy
The term “biotherapy” is sometimes used interchangeably with “biological therapy” or “biologic therapy,” and it can cause confusion because it overlaps with but is not identical to “immunotherapy.” In breast cancer, biotherapy broadly covers any treatment derived from living organisms or designed to interact with biological processes in a targeted way, rather than killing cells indiscriminately the way traditional chemotherapy does. This includes drugs that block specific proteins on cancer cells, drugs that recruit or unleash the immune system, and drugs that exploit genetic vulnerabilities in tumor DNA repair. Traditional therapies like surgery, radiation, and conventional chemotherapy remain important pillars, but they are limited by issues like drug resistance, collateral damage to healthy tissue, and inconsistent effectiveness across patients.1PubMed Central. Advancements in Immunotherapy for Breast Cancer: Mechanisms, Efficacy, and Future Directions Biotherapies were developed to address those gaps.
Breast cancer is not one disease. It is classified by the presence or absence of three receptors: estrogen receptor (ER), progesterone receptor (PR), and HER2. The major subtypes that matter for biotherapy decisions are hormone receptor-positive (HR+), HER2-positive, and triple-negative (TNBC, which lacks all three). Each subtype responds to different biological strategies, and a therapy that transforms outcomes in one subtype may do nothing for another.
HER2-Targeted Monoclonal Antibodies
The first major biotherapy success story in breast cancer was trastuzumab (Herceptin), a monoclonal antibody that targets the HER2 protein. HER2 is overexpressed in roughly 20 to 30 percent of breast cancers, and before trastuzumab, HER2-positive disease carried a particularly poor prognosis.2PubMed Central. Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer Trastuzumab was the first monoclonal antibody designed to block a cancer-driving protein, and its development earned its creators a Lasker Award for clinical research.3PubMed. Herceptin: A First Assault on Oncogenes that Launched a Revolution
Pertuzumab, a second HER2-targeted antibody, binds to a different part of the HER2 protein. The combination of trastuzumab and pertuzumab with chemotherapy is now an FDA-approved standard regimen for metastatic HER2-positive breast cancer.4PubMed Central. Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer When pertuzumab is added to trastuzumab and chemotherapy in early-stage HER2-positive breast cancer, patients gain improved disease-free survival without losing the ability to carry out their daily activities, though patient-reported diarrhea worsens during treatment and persists throughout the HER2-targeted therapy phase.5PubMed Central. Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer
Antibody-Drug Conjugates
Antibody-drug conjugates, or ADCs, are a newer category that combines the targeting ability of a monoclonal antibody with a potent chemotherapy payload. The antibody finds the cancer cell, attaches to it, and delivers the toxic drug directly. This limits the exposure of healthy tissue to the chemotherapy agent.
Trastuzumab deruxtecan (T-DXd) has been a game-changer. It targets HER2, but unlike older HER2 therapies, it works even in tumors with very low HER2 expression. Research has shown that T-DXd’s effectiveness in HER2-low and even HER2 “ultra-low” cancers comes from an unusual mechanism: an enzyme called cathepsin L, released by tumor cells into their surrounding environment, cleaves the drug’s linker outside the cell and releases the cytotoxic payload into the broader tumor neighborhood. This “bystander killing” bypasses the need for the cancer cell to actually internalize the drug, which is why T-DXd works where older ADCs like T-DM1, which require direct uptake by the cancer cell, do not.6Cancer Immunology Research. Abstract A059: Uncovering Bystander Killing Mechanisms of Trastuzumab Deruxtecan (T-DXd): Effective Extracellular Payload Release via Cathepsin L in HER2-low Breast Cancer
For triple-negative breast cancer, sacituzumab govitecan targets a different surface protein called Trop-2. In a pivotal trial, patients with metastatic TNBC who received sacituzumab govitecan had a median overall survival of about 12 months compared to roughly 7 months with standard chemotherapy, and the objective response rate was 35 percent versus 5 percent.7PubMed. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer A systematic review of clinical trials confirmed that sacituzumab govitecan provides a substantial clinical benefit over standard chemotherapy in TNBC and is expected to become a key part of future treatment guidelines.8PubMed Central. Sacituzumab Govitecan in Triple Negative Breast Cancer: A Systematic Review of Clinical Trials
Immune Checkpoint Inhibitors
Checkpoint inhibitors are the drugs most people think of when they hear “immunotherapy.” Cancer cells can evade the immune system by engaging molecular brakes on T cells. Checkpoint inhibitors release those brakes and let the immune system attack. In breast cancer, pembrolizumab (Keytruda) is the checkpoint inhibitor with the most evidence, and it is primarily used in triple-negative disease.
In early-stage TNBC, adding pembrolizumab to chemotherapy before surgery increased the rate of pathological complete response, meaning no detectable cancer remaining after surgery, to about 65 percent compared to about 51 percent with chemotherapy alone.9PubMed. Pembrolizumab for Early Triple-Negative Breast Cancer In the advanced or metastatic setting, pembrolizumab plus chemotherapy showed a meaningful survival benefit in patients whose tumors had higher levels of PD-L1 expression: median overall survival was 23 months versus about 16 months in the subgroup with the highest PD-L1 scores. In patients with lower PD-L1 expression, the survival benefit was not statistically significant.10PubMed. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer That distinction matters: checkpoint inhibitors do not help every breast cancer patient equally, and identifying who will benefit is one of the field’s biggest challenges.
PARP Inhibitors
PARP inhibitors exploit a weakness in the DNA repair machinery of certain cancers. Tumors that carry mutations in the BRCA1 or BRCA2 genes already have a broken DNA repair pathway. PARP enzymes handle a separate repair pathway; when you block PARP in cells that also lack functioning BRCA, the cell accumulates so much DNA damage it dies. This concept, called synthetic lethality, means targeting one pathway becomes deadly only when the other is already broken.11PubMed Central. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings
PARP inhibitors like olaparib and talazoparib are approved for breast cancers in patients who carry germline BRCA1 or BRCA2 mutations.12PubMed Central. PARP inhibitors: Synthetic lethality in the clinic These mutations are relatively uncommon in the overall breast cancer population but occur at higher rates in triple-negative breast cancer and in certain high-risk populations. PARP inhibitors are not used broadly across all subtypes; genetic testing is needed to identify candidates.
CDK4/6 Inhibitors
For hormone receptor-positive, HER2-negative breast cancer, the most common subtype, CDK4/6 inhibitors like palbociclib, ribociclib, and abemaciclib have become the standard first-line treatment in the metastatic setting when combined with endocrine (hormonal) therapy.13PubMed. Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer These drugs block proteins that drive cell division. When paired with hormonal therapy, they substantially extend the time before the cancer progresses. A real clinical challenge, however, is that resistance eventually develops, and the field is actively studying what to do next after CDK4/6 inhibitor-based treatment stops working.14PubMed. Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer
How Doctors Decide Which Biotherapy Fits
Selecting the right biotherapy depends on biomarkers, which are measurable characteristics of the tumor. The two most relevant biomarkers in current practice are PD-L1 expression and tumor-infiltrating lymphocytes (TILs). PD-L1 expression in breast cancer shows up in roughly 10 to 30 percent of cases, though the numbers vary widely depending on the tumor stage, subtype, and the specific testing method used.15PubMed Central. Tumor Infiltrating Lymphocytes (TILS) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications from Pathologist’s Perspective That variability is part of the problem. There is still no consensus on the best cutoff score or testing method for PD-L1 in breast cancer, which makes treatment decisions less clear-cut than oncologists would like.
TILs, the immune cells that have migrated into the tumor, are more common in triple-negative and HER2-positive breast cancers. Higher TIL levels in these subtypes predict a better response to chemotherapy and improved survival. Emerging data suggest that a TIL threshold of 5 to 10 percent, combined with PD-L1 expression, can help identify “immune-enriched” tumors most likely to benefit from checkpoint inhibitors.16PubMed. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition For HER2-positive disease, the decision is more straightforward: if HER2 is overexpressed, HER2-targeted therapies are indicated. For HR+ disease, hormonal therapy with CDK4/6 inhibitors is the default. The biomarker landscape gets most complicated in triple-negative breast cancer, where the subtype itself doesn’t point toward one obvious target.
Side Effects of Biotherapies
Biotherapies are often described as “targeted” and therefore assumed to be gentle. That is only partly true. While they generally produce fewer of the classic chemotherapy side effects like severe nausea and hair loss, they come with their own distinct adverse effects.
Checkpoint inhibitors like pembrolizumab can trigger immune-related adverse events, where the unleashed immune system attacks healthy tissue. In breast cancer trials, the most common of these included:
- Infusion reactions: roughly 18 percent of patients
- Hypothyroidism: about 15 percent
- Severe skin reactions: around 6 percent
- Hyperthyroidism: about 5 percent
- Rarer events: adrenal insufficiency, pneumonitis, colitis, and hepatitis, each affecting 1 to 2 percent of patients
These figures come from clinical practice guidelines for immunotherapy in breast cancer.17PubMed Central. Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for the treatment of breast cancer The thyroid problems are particularly common and often permanent, requiring lifelong hormone replacement. The lung and liver inflammation, while rarer, can be serious enough to require stopping treatment.
HER2-targeted therapies carry their own profile. Trastuzumab is associated with cardiotoxicity, meaning heart muscle damage, which requires cardiac monitoring during treatment. Pertuzumab’s main added burden is persistent diarrhea.18PubMed Central. Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer ADCs like sacituzumab govitecan can cause significant neutropenia (dangerously low white blood cell counts) and diarrhea, and T-DXd carries a risk of interstitial lung disease, a potentially fatal complication that requires careful monitoring.
One study comparing quality of life across treatment types in advanced breast cancer found that patients on targeted therapy reported fewer and milder symptoms than those on traditional chemotherapy, with hormonal therapy producing the least side-effect burden overall.19PubMed Central. Quality of life during chemotherapy, hormonotherapy or antiHER2 therapy of patients with advanced, metastatic breast cancer in clinical practice
Why Biotherapies Stop Working
Resistance is the single biggest limitation of biotherapy in breast cancer. Even tumors that initially respond well can develop escape mechanisms. In HER2-positive disease, resistance to trastuzumab and pertuzumab can arise from alterations to the HER2 receptor itself, activation of alternative signaling pathways that bypass HER2, or defects in cell death mechanisms.20PubMed Central. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications
For checkpoint inhibitors in triple-negative breast cancer, the resistance picture is especially complex. Tumors can evade the immune response through a wide range of mechanisms: low numbers of mutations for the immune system to recognize, problems presenting those mutations on the cell surface, shifts in the immune cell population surrounding the tumor, and metabolic changes that create an environment hostile to immune cells.21PubMed Central. Breast cancer resistance mechanisms: challenges to immunotherapy Some tumors are resistant from the start; others acquire resistance after an initial response.22PubMed Central. Immunotherapy in triple-negative breast cancer: mechanisms of resistance and emerging approaches: a narrative review Overcoming resistance often requires combination strategies, which is where much of the current research is focused.
Experimental and Emerging Approaches
Several biotherapy categories remain in earlier stages of development for breast cancer. These are not yet standard care, but they are generating active clinical research.
CAR-T cell therapy, which involves engineering a patient’s own immune cells to recognize and kill cancer cells, has been remarkably successful against blood cancers like leukemia and lymphoma. In breast cancer, the results so far have been disappointing. The main obstacles are the scarcity of tumor-specific surface markers that distinguish breast cancer cells from healthy tissue and the immunosuppressive environment within solid tumors, which can shut down CAR-T cells before they do their job.23Cancer Treatment Reviews. CAR-T cell therapy for breast cancer: Current status and future perspective Researchers are testing various strategies to improve CAR-T performance, including arming the engineered cells with additional molecules to resist the tumor’s immune-suppressing signals.24PubMed Central. CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application
Cancer vaccines are another area of active investigation. Unlike preventive vaccines, these are designed to train the immune system to recognize and attack tumor-specific proteins after cancer has already developed. Neoantigen vaccines, which are tailored to the unique mutations in a patient’s individual tumor, have shown an ability to provoke immune responses, and trials are evaluating whether they can prevent recurrence in high-risk patients who have completed standard treatment.25PubMed. Peptide vaccines in early breast cancer The appeal is a long-lasting, highly specific immune memory against the cancer, but no breast cancer vaccine has yet reached routine clinical use.
Oncolytic virotherapy uses modified viruses that selectively infect and destroy cancer cells while leaving healthy cells alone. Beyond directly killing tumor cells, these viruses remodel the tumor’s local environment and trigger an immune response. One of the most promising applications is their potential to turn immunologically “cold” tumors, meaning tumors that the immune system largely ignores, into “hot” ones packed with immune cells.26PubMed Central. Oncolytic virotherapy: new weapon for breast cancer treatment In mouse models of triple-negative breast cancer, a modified virus called VSV-S dramatically reduced lung metastasis after primary tumor removal and increased survival. It also boosted PD-L1 expression in tumors, which enhanced the effectiveness of checkpoint inhibitor treatment given afterward.27PubMed Central. Enhancing the Efficacy of Breast Cancer Immunotherapy Using a Smac-Armed Oncolytic Virus The combination of oncolytic viruses with other immunotherapies is a particularly active research front.28PubMed. Oncolytic virus-based combination therapy in breast cancer
Combining Biotherapies and Other Treatments
Breast cancer treatment increasingly relies on combining biotherapies with each other or with chemotherapy, radiation, and epigenetic drugs. The rationale is straightforward: cancer is rarely defeated by a single mechanism, and combining approaches can attack the tumor from multiple angles and make resistance harder to develop. Combining immune checkpoint blockade with epigenetic therapies, which modify how genes are turned on and off without changing the DNA sequence, has shown early promise in improving clinical outcomes.29PubMed Central. Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review
The pattern across the field is clear: almost every new biotherapy approval in breast cancer involves a combination regimen rather than a single agent used alone. Pembrolizumab is approved alongside chemotherapy. Pertuzumab is always used with trastuzumab and a chemotherapy agent. CDK4/6 inhibitors are paired with endocrine therapy. This is why resistance after combination treatment is such a difficult clinical problem: once a multi-drug regimen fails, fewer proven options remain.
Cost and Access
Biotherapies are expensive. Monoclonal antibodies, ADCs, checkpoint inhibitors, and CDK4/6 inhibitors can cost tens of thousands of dollars per treatment cycle. In developing countries, the price of biologic agents like trastuzumab has historically put them out of reach for the majority of patients. Biosimilars, which are near-identical copies of biologic drugs approved after the original’s patent expires, have begun to address this gap. By lowering treatment costs, biosimilars are increasing population-level access to HER2-targeted therapy, especially in underserved areas where biologic therapy was previously unavailable.30Academic Press. Biosimilars and biologics in breast cancer Several trastuzumab biosimilars are now approved in the United States and Europe, and their adoption is slowly expanding access, though cost barriers remain significant for newer agents that have no biosimilar competition yet.
The Gut Microbiome Connection
An unexpected area of research links the effectiveness of biotherapy to the bacteria living in a patient’s gut. Preclinical studies have shown that the composition of the gut microbiome can influence how well checkpoint inhibitors work. Specific bacterial species, including Bifidobacterium and Akkermansia, have been associated with enhanced immune responses to checkpoint blockade.31PubMed Central. Gut Microbiota and Extraintestinal Cancers: Mechanistic Insights and Microbiome-Targeted Interventions In HER2-positive breast cancer models, probiotics have been shown to modify the gut microbiome in ways that amplify the antitumor effects of checkpoint inhibitors, promoting interactions with cytotoxic T cells.32PubMed. Probiotics-Mediated Enhancement of Checkpoint Inhibitor Blockade for HER2+ Breast Cancer
This research is still largely preclinical, meaning it has been demonstrated in animal models rather than proven in human patients. But it points to an intriguing possibility: that something as simple as the state of your gut bacteria might partly determine whether an expensive and carefully chosen biotherapy works for you. Clinical trials investigating microbiome-targeted interventions alongside breast cancer immunotherapy are underway, though it is too early to make dietary or supplement recommendations based on this work.